Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 390.32% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$11.8 million (down 632.97% YoY), while the FY2025 annual figure was -$4.6 million, up 80.51% from the prior year.
• Change in Accured Expenses was -$5.3 million for Q1 2026 at Maravai Lifesciences Holdings, up from -$13.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $24.2 million in Q1 2023 to a low of -$24.1 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$578882.4 across 5 years, with a median of $1.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 882.5% in 2022, then plunged 870.77% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$5.6 million in 2022, then jumped by 213.99% to $6.4 million in 2023, then slumped by 124.45% to -$1.6 million in 2024, then sank by 764.07% to -$13.5 million in 2025, then surged by 60.52% to -$5.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.3 million (Q1 2026), -$13.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.